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Granulocyte-Macrophage  Colony-Stimulating  Factor,  Phorbol  Ester, 
and  Sodium  Butyrate  Induce  the CDl lc  Integrin  Gene  Promoter  Activity 
During  Myeloid  Cell  Differentiation 
By Miguel A. Rubio, Cristina Lopez-Rodriguez, Arsenio Nueda, Patricio Aller, Angel L. Armesilla, Miguel A.  Vega, 
and Angel L. Corbi 
To  analyze the activity of the  CDllc promoter during my- 
eloid differentiation without the  limitations of transient ex- 
pression systems, we have stably transfected the myeloid 
U937 cell line with  the pCDllC36l-Luc plasmid, in which the 
expression of the firefly luciferase cDNA is driven by the 
CDllc promoter region -361/+43, previously shown to con- 
fer myeloid specificity to reporter genes.  The stable  transfec- 
tants (U937-C361) retained the a b i l i   t o  differentiate in re- 
sponse to phorbol-ester (PMA), sodium butyrate (SB), 
granulocyte-macrophage colony-stimulating factor (GM- 
CSF), and other differentiating agents. U9374361 differenti- 
ation correlated with increased cellular luciferase levels, 
showing the inducibility of the CD1 l e  promoter during my- 
eloid differentiation and establishing the U937-C361 cells as 
a suitable system for studying the myeloid differentiation- 
inducing capacity of cytokines, growth factors, and other 
biological response modifiers. Unexpectedly, the inducibility 
of the  CDllc gene promoter showed distinct kinetics and 
URING MYELOID DIFFEFWNTIATION, hematopoi- 
etic stem cells become committed to myeloid precur- 
sors that later differentiate into fully functional end-stage 
cells, a process which is accompanied by the coordinate 
expression and repression of numerous genes.' Myeloid leu- 
kemic cells are arrested at distinct stages of the differentia- 
tion pathway, and a number of myeloid leukemic cell lines 
have been established that can be induced to acquire a more 
mature phenotype and, therefore, have been used to study 
the expression of myeloid differentiation-regulated genes.' 
The potential therapeutic implications of differentiation-in- 
ducing agents have been underscored by the successful appli- 
cation of the differentiation therapy in patients with acute 
promyelocytic leukemia.' 
Myeloid cell adhesion and differentiation are closely inter- 
regulated processes. Although adhesion to extracellular ma- 
trix components and neighboring cells is required for the 
proper completion of the cellular differentiation p r ~ g r a m , ~  
the pattern of expression of adhesion receptors greatly 
changes during myeloid differentiation? Most cell-adhesive 
interactions are mediated by Integrins, a family of cell sur- 
face heterodimeric glycoproteins involved in both intercellu- 
lar adhesion and in cell-extracellular matrix interactions. The 
members of the 0 2  integrin subfamily, ie, lymphocyte func- 
tion-associated antigen-l (LFA-l),  Mac-l, and p150,95 
(CD1 la-c/CD18), which play a key role in myeloid cell/ 
endothelium interactions during immune and inflammatory 
reactions: are leukocyte-specific. LFA-1 is expressed on all 
leukocytes, whereas Mac-l and p150,95 are almost exclu- 
sively expressed on myeloid  cell^.^.^ The expression of the 
02 integrins is tightly regulated during cellular differentia- 
tion.'.' Myeloid progenitor cells sequentially acquire the ex- 
pression of the leukocyte integrins during the early stages of 
differentiation,' and terminally differentiated myeloid cells 
express LFA-1, Mac-l, and ~150,95.~- '  The expression of 
Mac-l and p150,95 is induced during differentiation of the 
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magnitude on the PMA-,  SB-, or  GM-CSF-triggered differen- 
tiation. Moreover, SB synergized with either PMA or  GM- 
CSF in enhancing both the CDllc promoter activity and the 
cell surface expression of ~150.95 on differentiating U937 
cells.  Furthermore, we showed the existence  of  a c-Myb- 
binding site  at -85, the importance of  the -99/-61 region 
in  the  CDllc promoter inducibility during PMA-  or SB-trig- 
gered differentiation, and the dependency  of the GM-CSF 
and PMA  responsiveness of the CD1 IC promoter on an intact 
AP-l-binding site located at -60. These results, together 
with  the lack of functional effect of mutations disrupting the 
Spl- and Myb-binding sites within  the proximal region of the 
CDllc promoter, indicate that  the myeloid differentiation 
pathways initiated by SB and phorbol esters (or GM-CSF) 
activate a distinct set of transcription factors and show that 
the myeloid differentiation-inducibility of the  CDllc gene 
maps to the -99/-53 proximal region of the promoter. 
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myeloid cell lines HL-60 and U937, because of transcrip- 
tional mechanisms acting on their respective a-subunit 
genes.' The characterization of the CD1 lb'"'' and CD1 1c" 
gene promoter regions has shown their involvement in the 
tissue-specific expression of Mac-l and p150,95'0"2 and has 
shown the presence of initiator (Inr) sequences at their re- 
spective transcriptional start sites.'&'' 
U937 cells, a histiocytic lymphoma line with monoblast- 
like characteristics, can be induced to differentiate towards 
morphologically mature macrophage-like cells after treat- 
ment  with agents such as phorbol myristate acetate 
(PMA),'.I3 granulocyte-macrophage colony-stimulating fac- 
tor (GM-CSF),73'4 or sodium butyrate (SB).I5 To define the 
molecular basis for the p150,95 integrin induction during 
myeloid differentiation, U937 cells were stably transfected 
with a CD1 IC promoter-based reporter gene construct 
(U937-C361) and were used to characterize the activity of 
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the CD1 IC gene  promoter  in response to differentiation-trig- 
gering agents. Our results point out the usefulness of the 
derived U937-C361 cell line in determining the differentia- 
tion-inducing ability of other growth factors, cytokines, and 
biological response modifiers, show the inducibility of the 
CD1 IC gene promoter during the PMA-, SB-, or GM-CSF- 
stimulated myeloid differentiation, and identify DNA se- 
quence elements that confer the differentiation-inducibility 
to the CD1 IC promoter. 
MATERIALS AND METHODS 
Cell culture and transfection. U937 cells were grown in RPMI 
supplemented with 5% fetal calf serum, 2 mmol/L glutamine, and 
50 pg/mL gentamicin (complete medium), at 37°C in a humidified 
atmosphere with 5% CO,. For stable transfectants, U937 cells (1 to 
2 X lo7) were electroporated (100 V, 2,950 microfarads, 186 CL) in 
500 pL RPMI containing 40  pg of BamHI-linearized pCDllC361- 
Luc and 10  pg of BamHI-linearized pSV2-ne0.”.’~ After transfec- 
tion, cells were suspended in complete medium, cultured for 48 
hours, and maintained in complete medium supplemented with G418 
(1.5 mg/mL). Once cell growth was evident, cells were harvested, 
and the (3418-selected population (U937-C361) was subjected to 
cloning by limiting dilution. For induction of differentiation, U937 
or U937C-361 cells were resuspended in fresh complete medium ( S  
X IO’/mL), cultured for 9/12 hours and then treated with PMA 
(10 ng/mL), l-oleoyl-2-acetyl-glycerol (OAG; 20 pg/mL), GM-CSF 
(100 U/mL), 1,25 dihydroxyvitamin D3 (IO-* mol/L; kindly pro- 
vided by Dr M. Uskokovic, Hoffmann-La Roche), dimethyl sulfox- 
ide (DMSO; 1.4%), y-interferon (200 UlmL), etoposide (VP-16, 2 
X mom), amacrine (AMSA; 10” mol/L), or SB (1 mmol/L) 
for up to 5 days. At the indicated time points, cells were harvested, 
washed, counted, and lysed. Unless otherwise indicated, luciferase 
determination was usually performed on lo5 cells from each culture 
condition using a Berthold Lumat LB 9501 luminometer, as de- 
scribed,” and measuring light emission for 20 seconds. Output was 
quantitated as relative light units (RLU). 
The deletion mutants from the CD1 I C  promoter pCDllC361- 
Luc, pCDl 1C253-Luc, and pCDl  lC160-Luc, containing the regions 
-361/+43,  -253/+43, or -160/+43, respectively, have been pre- 
viously described.” Additional deletion constructs pCD 1 lC99-Luc, 
pCDl lC61-Luc, and pCDl IC53-Luc. including the regions -99/ 
+43, -61/+43, and -53/+43, were constructed after polymerase 
chain reaction (PCR) amplification of the corresponding fragments 
and ligation into the pXP2 plasmid. Site-directed mutagenesis of the 
Spl-70 site into a non-Spl-binding sequence was performed by 
standard proceduresL7 and will be described elsewhere (C. L6pez- 
Rodriguez, A.L. Corbi, manuscript submitted). The reporter plasmid 
containing a mutation  at Spl-70 was termed pCDllC160(-70MUT)- 
Luc. The pCDl IC361(-85MUT)-Luc plasmid, was derived from 
pCDllC361-Luc after mutation of the Myb-binding site at -85 by 
site-directed m~tagenesis’~ using an oligouncleotide later used for 
electrophoretic mobility shift assay (EMSA) studies (mBoxD, see 
below). pCDllC160(-85)-Luc was constructed by PCR on 
pCDl  c361(-85)-Luc, using oligonucleotides (-160) 5’-CTT- 
GGATCCAAGCCAAGTCATCTGATGAGAG -3’ (- 138) (sense, 
CD1 I C  pXP2 - 160) and (+43) 5’- GATCTCGAGCTCCTG- 
GGCCG-3’ (+28) (antisense, CD1 I C  pXP2 +43) as PCR primers to 
amplify the whole CD1 IC promoter-derived insert and using further 
cloning into pXP2. The pXP2-derived pCDl1 A100-Luc plasmid, in 
which the expression of the luciferase cDNA is driven by the - 1 0 0 /  
+83 fragment from the CD1 la promoter,“ was used as additional 
control in some experiments. All mutations and constructs were 
confirmed by sequencing and were electroporated in U937 cells, as 
described.’’ After transfection, cells were split into 4 aliquots and 
either were left unueated or were cultured in the presence of PMA, 
GM-CSF, or SB. Fourteen hours after transfection, luciferase activi- 
ties were determined. For comparative purposes, the “Promoter Ac- 
tivity Induction” of the differentiating agents on each construct was 
defined as the ratio of RLU in treated transfected cells to RLU in 
untreated transfected cells, after background subtraction and nor- 
malizing for cell number in each culture condition. A similar calcula- 
tion was used to determine the effect of the differentiation-inducing 
agents on the luciferase activity in U937-C361 cells. When neces- 
sary, transfection efficiencies were normalized by including 20 pg 
of the pSVpgal plasmid in the electroporation mixture, and luciferase 
activities were determined on cell extracts containing identical p- 
galactosidase activity. In  all cases, at least two distinct plasmid 
preparations of each deletion construct were tested by transfection. 
Immunojuorescence analysis. U937 cells or U937-C361 
transfectants were subjected to treatment with differentiation agents 
as indicated, harvested, washed in ice-cold phosphate-buffered sa- 
line, and resuspended in 100 pL of the following hybridoma culture 
supernatants: Bear-l (anti-CD1 Ib), HClll  (anti-CDIlc), and TSI/ 
18 (anti-CD1 8). After washing, bound antibodies were detected us- 
ing fluorescein-conjugated F(ab‘), rabbit antimouse Ig, and cells 
were analyzed on a FACScan cytofluorometer. All incubations were 
performed in the presence of 1 % human AB serum to prevent binding 
through the Fc portion of the antibodies. The supernatant from the 
myeloma P3X63 was included as negative control. 
Southern and Northern blot. Genomic DNA was isolated from 
the selected U937-C361 clones, and 10-1.18 aliquots were digested 
with EcoRI and BamHI. After electrophoresis and transfer onto nylon 
membranes using 1OX saline sodium citrate (SSC), filters were pre- 
hybridized and hybridized as described,“ using a 616-bp Xho I- 
EcoRI fragment from the luciferase cDNA and a 404-bp BamHI- 
Xho I fragment from the CDl lc  promoter as probes. Both DNA 
fragments are contiguous in the pCDllC361-Luc plasmid used to 
establish the stable transfectants.” Membranes were sequentially 
washed in 2X SSC and 0.5% sodium dodecyl sulfate at room temper- 
ature (for 45 minutes) and in 0.3X SSC and 0.5% sodium dodecyl 
sulfate at 37°C (for 15 minutes) and 65°C (10 minutes), and were 
exposed at -70°C with an intensifying screen. Northern blot was 
performed on total RNA isolated from untreated and PMA-, GM- 
CSF-,  or SB-treated U937-C361 cells? using a  0.8-kb Pst I fragment 
from the CD1 I C  cDNA, a 1.2-kb EcoRI-Hind111 fragment from the 
c-my cDNA, and a  I-kb Pst I fragment from the P-actin cDNA,’ 
as probes. 
EMSA. A total of 50 ng of the CD1 IC promoter-based double- 
stranded oligonucleotides BoxD, mBoxD, or 2xMyb oligo’” were 
labeled using avian myeloblastosis virus (AMV) reverse tran- 
scriptase (7 U) and 50 pCi of either 32P-deoxyguanosine triphosphate 
or 3’P-deoxycytidine triphosphate (specific activities, = I O8 cpdpg) .  
A total of 0.5 ng of probe was then incubated at  4°C with 2 pL of 
bacterial extracts containing c-Myb or with control bacterial extracts 
in 20 pL containing 28 mmol/L EDTA, 15 mmoVL KCI, 6 mmol/ 
L MgCL, 7 mmol/L HEPES (pH 7.9 at 4 T ) ,  7% glycerol, I mmol/ 
L dithiothreitol, and 2.5 pg poly (dI-dC). Unlabeled competitor oli- 
gonucleotides were added at 500 molar excess in competition assays 
and were incubated at 4°C for 15 minutes before the addition of  the 
radioactive probe. Binding reactions were incubated for 20 minutes 
at 4°C. and 1.5 pL of a lox loading buffer (10 mmol/L HEPES, 
IO% glycerol, 0.01% bromophenol blue) was added to the reaction. 
A total of 12 pL of each reaction was separated by electrophoresis 
at 15 V/cm and 4°C on 4% to 5% polyacrylamide gels containing 
0 . 4 ~  TBE (45 mmoVL Tris base, 45 mmol/L boric acid, 1 mmoVL 
EDTA) until free probe was close to the bottom of the gel, and  with 
buffer recirculation every 15 minutes. The oligonucleotides used for 
EMSA were the CD1 I C  promoter-derived BoxD (-94 CCTCGGAT- 
CAGTTG CGTACTCTGCC -70); mBoxD (5”CCTCGGATGTC- 
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GACCGTACTCTGCC-3‘),I2  which  has  mutated  the  putative Myb- 
or  bHLH-binding  site  CANNTG;  2xMyb  (5”TAGAATAACGG 
AAGCAATAACGG AA-3’), which  includes two Myb-binding  sites; 
and m(2xMyb) (5’-TAGAATCCAGGAAGCAATCCAGG AA-3’), 
which has  both  Myb-binding  sites  mutated.I8  Extracts  from  bacteria 
transformed  with  the  c-Myb  cDNA  in  pFLAG-1  or  the  control  empty 
vector (kindly provided  by  Drs  T.  Bellon and B.  Calabretta;  Jefferson 
Cancer  Institute,  Philadelphia,  PA)  were  prepared by sonication of 
bacterial  cultures  grown in the  presence  of  isopropyl  P-D-thiogalac- 
topyranoside  (IPTG)  for 5 hours. 
RESULTS 
Stable  transfection of U937  cells  with a  CD1 IC promoter/ 
luciferase reporter construct. We have previously isolated 
and functionally characterized the CD1 IC gene promoter and 
shown its tissue-specific activity in myeloid and CD1 IC+ B- 
lymphoblastoid cells.“ To analyze the activity of the CD1 l c  
promoter during myeloid differentiation, U937 cells were 
transfected with the pCDllC361-Luc and the pSV2-neo 
plasmids. The G41 8-selected cell population (U937-C361) 
showed the same doubling time as untreated U937 cells and 
showed a measurable level of basal luciferase activity that 
increased on PMA-triggered differentiation (data not 
shown). Limiting dilution cloning led to the isolation of a 
number of clones whose levels of background luciferase 
activity were constant during long-term culture and ranged 
between 300 and 40,000 RLU/105 cells (Fig 1A). More im- 
portantly, PMA-stimulated cell differentiation led to a 4- to 
12-fold increase in the endogenous luciferase activity of the 
isolated clones, an induction of similar magnitude to that 
previously reported for the pCDllC361-Luc plasmid on 
transient expression in U937 cells (Fig lB).” Hybridization 
with a luciferase cDNA probe showed that the copy number 
of the construct in the distinct U937-C361-derived clones 
was variable and correlated with their basal level of lucifer- 
ase (Fig 1C). Probing of a similar blot with the -361/+43 
fragment from the CD1 IC promoter showed that the insertion 
had not affected the structure of the construct because both 
probes hybridized to a common set of bands (Fig 1C). Given 
the colinearity of the CD 1 IC promoter and the luciferase 
cDNA in the transfected construct,’* the PMA-mediated in- 
crease of the luciferase level in the isolated clones reflects 
the differentiation-inducible activity of the CD1 IC promoter 
and is not caused by positional effects. The U937-C361 clone 
no. 2 (U937-C361#2) was chosen for further analysis based 
on its low but significant luciferase level under normal cul- 
ture conditions (see Figs 1A and B). 
Immunofluorescence analysis showed that, as previously 
described for U937 the isolated U937-C361 clones 
lacked Mac-l and p150,95 cell surface expression, which 
were detected only on PMA-stimulated differentiation (Fig 
1 D).  PMA addition also promoted LFA- Mntercellular adhe- 
sion molecule- 1 -mediated homotypic aggregation with sim- 
ilar kinetics in both U937 and U937-C361 cells (Fig 1E). As 
a whole, the differentiation-associated phenotypic changes in 
U937-C361 cells were indistinguishable from those observed 
in  U937 cells, indicating that the differentiation capacity of 
the parental cell line had not been altered by the insertion 
of the pCDllC361-Luc construct. 
Effect of proten kinase C (PKC)-activation on the lucifer- 
ase  levels in U937-C361#2. Although PMA and OAG acti- 
vate PKC, OAG can neither promote U937 differentiation 
nor induce the expression of p150,95 (Calabretta” and our 
unpublished results). PMA or OAG treatment of U937- 
C361#2 cells caused a small transient increase in luciferase 
activity, that returned to basal levels 6 to 9 hours after treat- 
ment (Fig 2A), an effect also observed on addition of fresh 
serum or replacement of the culture medium (data not 
shown) and which is consistent with the presence of an AP- 
1 sequence within the transfected construct.” However, at 
later time points, OAG-treated cells showed basal levels of 
luciferase activity, whereas the luciferase level in PMA- 
treated cells constantly increased up to 5 days after the phor- 
bol-ester addition (Fig 2A), which is in agreement with the 
previously described activity of the CDl lc  promoter in 
PMA-treated U937 cells?’* Therefore, as with  U937 differ- 
entiation, the induction of luciferase activity in  U937- 
C361#2 requires the continuous activation of PKC  and  sup- 
ports the lack of differentiation-inducing ability of OAG in 
U937  cell^.'^ Furthermore, whereas PMA differentiation led 
to the appearance of CD1 IC on the cell surface, OAG had 
no effect on the p150,95 expression (data not shown). These 
results show that U937-C361#2 cells respond to PKC activa- 
tors in the same manner as the parental U937 cell line 
and, more importantly, that the luciferase activity in 
U937-C361#2 cells reflects the differentiation state of the 
cells. 
Effect of SB and GM-CSF on the luciferase activity in 
U937-C361  cells. U937 cells have been previously re- 
ported to differentiate in response to SBL5 and GM-CSF?l4 
and, in both cases, the expression of CD1 lc/CD18 is induced 
during the pro~ess.’.’~ As shown in Fig 2B, luciferase level 
augmented during both SB- or GM-CSF-driven differentia- 
tion, although with different kinetics (Fig 2B), whereas 
agents that do not alter the differentiation state of U937 cells 
(y-interferon at 200 or 2,000 U/mL) left the luciferase levels 
unaltered (data not shown). During SB differentiation, lucif- 
erase activity increased greater than 25-fold at 24 hours, thus 
correlating with the appearance of CD1 IC on the cell surface 
(see Fig 3C), and almost returned to basal levels after 72 
hours (Fig 2B). Following a similar kinetic profile as that 
used during PMA-triggered differentiation, the increase was 
considerably slower during GM-CSF differentiation, with a 
2- to 4-fold increase between 24 and 72 hours and a maximal 
induction after 5 days (5-fold; see Fig 2B), which is in 
agreement with the later apperance of CDl lc  on the mem- 
brane (Fig 3C). Northern blot showed the presence of CD1 IC 
mRNA 24 hours after the addition of each differentiation 
agent, a time at which c-myc mRNA had  been already down- 
regulated (Fig 2C). At all time points analyzed, PMA 
induced higher levels of CDl lc  mRNA than did SB or 
GM-CSF, a fact probably related to the slight c-myc mRNA 
reinduction observed 48  to 72 hours after GM-CSF or SB 
treatment (Fig 2C). Altogether, and allowing for some quan- 
titative differences because of posttranscriptional mecha- 
nisms, luciferase activity levels correlate with both the ex- 
pression of the endogenous CDl lc  gene and the c-myc 
mRNA downregulation and, therefore, may be considered 
as a differentiation marker in U937-C361 cells. 
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Fig 1. Characterization of the U937 cells stably  transfected with the  pCDllC361-Luc  plasmid  is shown. (A) Basal activity  of  the CDl lc 
promoter  by seven U937-C361 independent clones during  normal in vitro  culture conditions, as determined  by luciferase activity. (B) The 
increase in luciferase activity caused by  the PMA-mediated differentiation  of  the seven isolated U937-C361 clones was  determined  by measuring 
the luciferase activity 24 hours after PMA treatment. Luciferase determinations  were  performed on '10' cells, and  the background level of the 
luminometer  was  always  lower  than 220 RLU. Promoter activity  induction  was calculated as determined under Materials  and Methods. (C) 
Detection of the  pCDllC361-Luc  plasmid DNA in U937-C361-derived clones was  performed by means of Southern  blot  on genomic DNA from 
the U937-C361-derived clones (lanes 1-7) or  from  untreated U937 cells (lane U). Two identical membranes were  hybridized with either an Xho 
I-€COW luciferase cDNA probe  (right)  or  the BamHI-Xho I CDllc promoter  fragment (left). A schematic representation of the  pCDllC361-Luc 
plasmid, with  the relative  position  of each probe, is  shown  at  the  top. The black circle indicates the  position  of  the genomic CDl lc promoter, 
and  the  arrow signals the BarnHI-EcoRI fragment  that includes both probes. (D) Comparative differentiation capacity of U937 cells and the 
U937-C361#2 transfectant as measured by  the expression of Mac-l  (CDllb/CD18)  and p150.95 (CDllclCD18)  on  untreated and PMA-differenti- 
ated cells. (E) Comparison of  the  homotypic  aggregation  on  PMA-differentiated U937 and U937-C361#2 cells is shown. 
SB- and PMA-triggered diferentiation synergistically in- 
duce the CDl lc  gene promoter activity and p150,95 cell 
su$ace expression. The distinct behavior of the CD1 I C  
promoter during the SB- and  PMA (or GM-CSF)-triggered 
differentiation prompted us to analyze whether their effects 
were additive. As shown in Fig 3, the luciferase activity 
induced during the PMA- or GM-CSF-triggered differentia- 
tion was further augmented in the presence of SB, giving 
rise to promoter activity induction values that ranged be- 
tween 50- and 100-fold. The presence of OAG during the 
SB-triggered differentiation had  no effect on the activity of 
the CD1 I C  promoter (data not shown), showing that transient 
PKC activation is not sufficient for the potentiating effect 
of SB. At the same time, p150,95 cell surface expression 
during the GM-CSF- or PMA-triggered differentiation was 
considerably higher in the presence of SB than  was  the ex- 
presion induced by either agent alone, especially at early 
time points. At 24 hours, the mean fluorescence intensity 
(MFI) for CD1 I C  was 27 in the case of SB differentiation, 
20 for the GM-CSF differentiation, and 49 in the presence 
of both agents, and the same synergistic effect was observed 
at 48 hours (MFI of 49, 17, and 67 with both agents; see 
Fig 3C). In addition, a similar effect could be observed when 
SB was present during the PMA-stimulated differentiation 
(MFI of 49 with SB, of 79 with  PMA,  and of 103 with  both 
differentiating agents; see Fig 3C). Altogether, the above 
results indicate that SB-triggered differentiation induces the 
CD1 I C  promoter activity with distinct kinetics than  PMA or 
GM-CSF,  and possibly through distinct signaling pathways. 
Luciferase levels were also determined after treatment 
with a distinct set of differentiating The DNA 
topoisomerase I1 inhibitor AMSA increased luciferase activ- 
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Fig 2. The effect  of PKC activators  and  differentiation-triggering 
agents on  the  CDllc gene promoter activity is shown. (A and B) 
U937-C361#2 cells were  either  untreated  or  treated in the presence 
of PMA 110 nglmL)  or OAG (20 pglmL; A) or  of GM-CSF (l00  UlmLl or 
SB (1 mmollL; B). At  the  indicated  time points, cells were harvested, 
counted, and lysed, and  their luciferase levels were determined. The 
promoter  activity  induction  reflects  the  activity  of  the CDl lc pro- 
moter and represents the  fold  induction of luciferase levels caused 
by  the  addkion  of each  agent, after  normalizing  for  cell number. Four 
independent experiments were performed, and a representative one 
is  shown. (C) Determination  of  the steady-state level of CDl lc mRNA 
(upper panel), c-myc mRNA (middle panel), and  p-actin mRNA (lower 
panel) in U937-C361#2 cells at the indicated time  points  during PMA-, 
GM-CSF-, or SB-triggered differentiation  is shown. 
ity with similar kinetics and to similar levels as those for 
GM-CSF, which  is in agreement with its ability to downregu- 
late c -my and to induce CD1 I C  expression (Fig 4).'"." Inter- 
estingly, the effect of VP-16, which also inhibits DNA topo- 
isomerase 11, was somewhat different as luciferase levels 
peaked  at 72 hours  and decreased afterwards (Fig 4). On the 
other hand, the polar solvent DMSO" triggered luciferase 
levels that were maximal at 48 hours  and  returned to basal 
levels at 120 hours. Therefore, the luciferase activity in re- 
sponse to DMSO and SB (Fig 2B and Fig 4) returned to 
background levels after 120 hours, a time at which other 
agents showed maximal activity (GM-CSF, AMSA, PMA) 
or still maintained augmented levels (VP-16). As a control, 
1,25 dihydroxyvitamin D3,  which induces incomplete U937 
differentiation,'3 failed to induce either the p150,95 expres- 
sion or the activity of the  CD1 I C  promoter (Fig 4). 
A 
B 
C 
m Butyrate + PMA 
0 24 48 72 96 120 
hour0 
0 24 48 72 9i3 l20 
hoUrS 
B 
5 
A 
SB 
m 
z 
W 
0 
LOG FLUORESCENCE  INTENSITY 
Fig 3. SS potentiates  the effect of PMA- (or GM-CSF-) triggered 
differentiation on the CDl lc promoter. U937-C361#2 cells were 
treated with SB and PMA (A)  or with SB and GM-CSF  (B), and  the 
luciferase levels were  determined  at  the  indicated  time points. Three 
independent experiments were performed, and a representative one 
is  shown. (C) Cell surface expression of p150,95 48 hours  after  the 
initiation  of each differentiation  protocol  is shown. The background 
immunofluorescence is  shown  for each culture  condition and is repre- 
sented by a stippled curve. 
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Fig 4. The effect of alternative U937 differentiating agents  on the 
CDllc promoter activity is shown. U937-C361#2 cells were treated 
in the presence of the indicated differentiation-triggering agents. The 
cells were harvested,  counted,  and  lysed, and their luciferase  levels 
were determined at  the indicated time points. The promoter activity 
induction represents the fold induction of  luciferase  levels  caused by 
the addition of  each agent. A representative experiment is presented. 
The expression of  p150.95 was determined in parallel by immunoflu- 
orescence analysis 48 hours after the start of each treatment. I+) 
indicates more than 60% of  CD1 IC+ cells, whereas (-1 represents less 
than 5%  of CDllc+ cells. 
Localization of the SB and GM-CSF differentiation-re- 
sponsive elements within the C D l l c  promoter. Transient 
expression of serial deletion mutants from the -361/+43 
fragment of the CD1 IC promoter showed that the differentia- 
tion-responsiveness of the CDl lc  promoter was retained in 
the -160/+43 region (Fig 5A). Moreover, the PMA, GM- 
CSF, and SB differentiation-responsiveness of additional 
deletion mutants (pCD1 lC99-Luc, pCDl lC61-Luc, and 
pCDllC53-Luc) was  not affected by deletion of the region 
contained between -160 and -99 (compare pCDllC160- 
Luc and pCDllC99-Luc; see Fig 5B). However, a further 
deletion reduced the SB differentiation-responsiveness by 
a factor of 7 (70.4- v 10.6-fold induction), showing SB- 
responsive elements within the region -99/-61 (Fig 5B). 
Removal of the consensus AP-1 sequence led to an addi- 
tional threefold decrease (10.6- v 3.6-fold; see Fig 5B), indi- 
cating that the AP-l sequence also contributes to the SB- 
responsiveness of the CD1 IC promoter. The remaining slight 
effect of SB  on pCDllC53-Luc was also observed in other 
reporter plasmids, including the control CD 1 1 a-derived 
pCDllA100-Luc plasmid (Fig 5B),16 thus suggesting a gen- 
eral effect on transcription. Regarding the PMA differentia- 
tion-responsiveness of the CD1 IC promoter, it  was substan- 
tially reduced by deleting the -99/-61 fragment and was 
completely abolished on removal of the AP-l-binding se- 
quence (-61) 5”CTGACTCAT -3’ (-53; see Fig 5B). The 
response to GM-CSF was unaffected by deletion of the -991 
-61 region (Fig 5B) and was only abrogated by deletion of 
the -61/-53 AP-l sequence (Fig 5B), which is in agreement 
with the GM-CSF ability to enhance AP-l activity in U937 
cells.’4 Therefore, it  can be concluded that the AP-1 sequence 
at -61/-53 is absolutely required for the CD1 I C  promoter 
responsiveness to PMA  and GM-CSF differentiation and that 
it also influences its SB-inducibility, although to a lower 
extent. 
Structural analysis on  the -99/-61 region showed a con- 
sensus Myb-binding site (PyAACG/TG) at -85 (CAACTG) 
that is also a consensus E-box binding site for members of 
the basic/helix-loop-helix (b/HLH) family of transcription 
factors (E box = CANNTG).I2 c-Myb was shown to  bind at 
-85 (CAACTG)(Myb-85, BoxD), because c-Myb-con- 
taining bacterial extracts, which specifically recognized the 
2xMyb consensus oligo, were able to  retard the BoxD dou- 
ble-stranded oligonucleotide (spanning from -94 to -70) 
but did not recognize the mBoxD probe, which lacks the 
Myb-binding site (Fig 6A). Moreover, BoxD inhibited the 
binding of Myb to 2xMyb, and the latter abrogated the  Myb- 
containing retarded species on the BoxD oligonucleotide 
(Fig 6A), thus clearly indicating that the CDl lc  proximal 
promoter is specifically recognized by the c-Myb transcrip- 
tion factor. The SB-responsiveness of the CD1 I C  promoter 
was then analyzed by eliminating either a previously de- 
scribed Spl-binding site (Spl-70) which is required for opti- 
mal basal promoter activity (C. Lopez-Rodriguez and A.L. 
Corbi, manuscript submitted) or the E-box/Myb-bind- 
ing site. Mutations that abrogated binding to Spl-70 
[pCDllC160(-70MUT)-Luc] or that simultaneously dis- 
rupted the E-box and the Myb-binding site at -85 
[pCDl 1C 160(-85MUT)-Luc] did not significantly inhibit 
the SB responsiveness of the CD 1 IC promoter in  the context 
of the -160/+43 fragment (Fig 6B) and also left unaltered 
the PMA differentiation inducibility of the promoter. These 
results showed that the SB inducibility of the CD1 I C  pro- 
moter is mediated by the -99/-61 proximal  promoter region 
but without the involvement of the ubiquitous Spl, the tis- 
sue-restricted Myb transcription factor, or any E-box-binding 
b/HLH factor. 
DISCUSSION 
The leukocyte integrin p150,95 (CD1 lc/CD18) constitutes 
a marker for mononuclear phagocytes24 and  is primarily ex- 
pressed on cells of the myeloid although it is also 
found on activated B lymphocytes and is highly expressed 
on  hairy cell leukemia ~ e l l s . ~ ~ . ~ ’  We have previously shown 
that the promoter region of the CD1 I C  gene directs the my- 
eloid-specific expression of p150,95 and is also active in 
CD1 IC+ B lymphoblastoid  cell^.^.'^ Given the limitations 
of transient expression assays for performing time-course 
analysis in  myeloid cells:* we have derived the U937-C361 
stable transfectant, have shown the responsiveness of the 
CDl lc  promoter to myeloid differentiation, and have shown 
that the CD1 I C  promoter activity is inducible by differentia- 
tion-triggering agents that differ in their mechanisms of ac- 
tion  and/or  target  DNA elements. Moreover, we have 
mapped the differentiation-response elements of the CD1 I C  
gene promoter to the -99/-53 region and have shown  the 
differential involvement of the AP-1-, Spl-, and  Myb-bind- 
ing sites located within this fragment. 
Comparison of the effects of three differentiation agents 
on the U937-C361 cells showed that PMA and GM-CSF 
induced the CDl lc  promoter activity with similar kinetics 
but  with different strength. Transient expression experiments 
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Fig 5. Mapping  of  the  differentiation-inducible  activity of the CD1 l e  gene promoter  is hown. The indicated CD1 IC promoter-based luciferase 
constructs  were  electroporated in U937  cells, and  the  transfected cells were  split and cultured in the presence of  the  distinct  differentiating 
agents or  were  left  untreated. (A) Mapping  of  the  differentiation-response lements to  the -160/+43 region  of the  CDllc promoter  is shown. 
(B) The involvement  of  the -61/-53 AP-1 consensus sequence and  the -99/-61 fragment in the PMA, GM-CSF, and SB responsiveness of 
the  CDllc promoter  is hown. Luciferase activity  was  determined after 14 hours," and  identical  results  were  obtained 24 hours  posttransfection. 
Promoter activity  induction represents the  fold  induction of the luciferase activity caused by each differentiating agent. In all cases, the  activity 
of  the  promoterless  plasmid pXP2 was  similar t o  the background level of the  luminometer (200 to  210  RLU for  a 20-second measuring time) 
and was  not  altered  during  cell  differentiation. Each construct  was assayed at least four times, and  a representative experiment  is  shown.  In 
the  experiments  shown  in (B), a CDl la promoter-based luciferase construct  ipCDllA100-Luc)'6  was used as an additional  control. 
lend further support to the existence of a common set of 
factors mediating the inducibility of the promoter during 
PMA- or GM-CSF-triggered differentiation. Although dele- 
tion  of  the -99/-61 region  only affected the  PMA inducibil- 
ity, elimination of the AP-I consensus sequence completely 
abrogated the responsiveness of the  CD1 1 c promoter to both 
agents. This finding  is in agreement with the previously re- 
ported capacity of GM-CSF to activate PKC  and to enhance 
the AP-I activity in U937 cells." Therefore, PMA and GM- 
CSF may induce the CD1 I C  promoter activity through a 
common pathway that would include activation of the AP- 
I complex, because the CD1 I C  -611-53 sequence has  been 
shown to be a functional AP-I site by both in vitro foot- 
printing and EMSAs (Lopez-Cabrera et all' and C. L6pez- 
Rodriguez  and A. L. Corbi, manuscript in preparation), and 
because maximal activation of AP-I in U937 cells has been 
shown to correlate with induction of differentiation mark- 
ers.'" Because c-jios and c-jun are known to cooperate for 
transcriptional activation with members of the ers gene fam- 
ily of transcription factors,'" some of which regulate the 
activity of the CD1 Ib promoter,'' it is possible that  such a 
cooperation also occurs at  the  CD1 I C  promoter. 
The CD1 I C  gene promoter shows an Inr element at the 
major transcriptional start site." Based on physical  and func- 
tional interactions between c-my and transcription factor 
11-1, i t  has been recently proposed that c -my may repress 
transcription initiation from TATA-less Inr-containing 
genes." If this is the case, the distinct magnitude of the 
CD1 I C  promoter induction during the PMA-  and GM-CSF- 
triggered differentiation might arise from their opposite ef- 
fects on c-my levels. PMA completely downregulates c-myc 
gene transcription in U937,37 whereas the downregulation of 
c-my by GM-CSF in U937 cells is transient (Fig 2C) and 
may correlate with the fact that  the GM-CSF signaling path- 
way in other cell types leads to induction of c-my." Site- 
directed mutagenesis will greatly help in the determination 
of the role that the Inr sequence might  play in the  induction 
of p150,95 during PMA-  and GM-CSF-triggered differenti- 
ation. 
A variety of low molecular weight polar solvents, such 
as SB or DMSO, can induce erythroid and myeloid cell 
differentiation,2""5.3h and SB-differentiation (and to a lower 
extent DMSO) produced a high and transient induction of 
the CD1 I C  promoter activity. The exact mechanism of action 
of SB is unknown. However, mutation of the Spl sites within 
the human immunodeficiency virus-long terminal repeat 
(HIV-LTR) completely eliminates its SB-inducible promoter 
activity, and a correlation between  the presence of functional 
Spl sites and SB-inducibility has been proposed.".'* Con- 
versely, mutation of the Spl-70 site within the CD1 I C  pro- 
moter" had no effect on the SB-inducibility, which was 
greatly inhibited by deletion of the -99/-61 region, there- 
fore suggesting distinct mechanisms for the SB-respon- 
siveness in different genes. Sequence analysis on the -99/ 
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-61  region  showed the overlapping presence of a consensus 
Myb-binding site (PyAACG/TG) and a consensus binding 
site for the members of the b/HLH family of transcription 
factors (CANNTG or E-box) at -85 (CAACTG)." In fact, 
structural studies showed that c-Myb is indeed capable of 
binding  to  the  CD1 I C  proximal promoter by recognition of 
the -85 CAACTG DNA element. Because both gene fami- 
lies (Myb and  WHLH) regulate gene expression during my- 
eloid differentiati~n,~'"" we tested the effect of mutations 
that disrupted both  the  E-box  and the Myb-binding site 
(CAACTG into GTCGAC). The lack of effect of this muta- 
tion indicates that additional proteins, distinct from  Myb  and 
b/HLH factors, mediate the SB inducibility of the CD1 I C  
promoter. Conversely, deletion studies suggested that the 
AP-I site slightly influences the SB-responsiveness, proba- 
bly because of the positive effect that SB has on the expres- 
sion of some members of the  AP-I transcription factor com- 
p l e ~ . ~ '  The identification of the specific DNA sequence 
mediating the SB responsiveness of the CD1 I C  promoter 
requires further mutagenesis studies on the identified -99/ 
-61 fragment. 
In addition to its differentiation-inducing capacity, SB 
synergizes with  PMA or GM-CSF in producing both a 
greater induction of the CD1 I C  promoter activity and a 
higher cell surface expression of p150,95. Because PMA  and 
GM-CSF activate PKC and stimulate the AP-I acti~ity,''."~ 
it is possible that the SB signaling pathway is potentiated 
2.1 
3.3 
ND 
1 .l 
Fig 6. The effect of  mutation  at  Spl-70  and  Myb- 
85 on the differentiation responsiveness of the 
CDl lc promoter is shown. (Al Binding of c-Myb- 
containing bacterial extracts t o  the -85 DNA ele- 
ment  on  the  CDllc  promoter  is  shown. EMSA was 
performed  on  the 2xMyb. BoxD, and mBoxD double- 
stranded oligonucleotides, using  extracts  from 
bacteria transformed with either c-Myb in pFLAG-1 
(indicated by rMybl or with an insertless plasmid 
(indicated as Control). In all cases, competitor  oligo- 
nucleotides were used at 500 molar excess. The posi- 
tion of the Myb retarded complex is indicated by 
brackets. (B1 The effect of mutations  at  Spl-70 or 
Myb-85 in the  myeloid  differentiation-inducibility of 
the  CDllc  promoter is  shown.  Wild-type and mutant 
Spl  and  Myb sequences are depicted as filled  and 
empty circles or ovals, respectively. In all cases, the 
activity of the  promoterless  plasmid pXP2 was  simi- 
lar to  the background level of the  luminometer 1200 
t o  210 RLU for  a 20-second measuring time1 and was 
not altered  during  cell  differentiation. Each construct 
was assayed at least three times, and a representa- 
tive  experiment  is shown. 
by agents whose differentiation-inducing activity is  mediated 
by AP-I (Fig 7). In this sense, SB also synergizes with 
the antioxidant pyrrolidine dithiocarbamate, which has been 
recently reported to activate AP-I (Meyer et aId2 and M. 
Rubio and A. Corbi, unpublished results). In any event, SB 
appears to be potentiated only by PKC activators with differ- 
entiation-inducing ability, because the SB-stimulated CD1 I C  
promoter activity was not altered by the concomitant pres- 
ence of OAG. A hypothetical model for the regulation of 
~150.95 during myeloid differentiation, shown in Fig 7, is 
based on the distinct mode of action of SB and the PKC 
activators (GM-CSF and PMA) and their synergistic effect 
on the induction of the CD1 I C  gene and assumes that the 
most relevant targets of their respective signaling pathways 
are the -99/-61 region (SB and PMA) and the AP-I se- 
quence (PMA, GM-CSF, and, to a lower extent, SB). 
Myeloid leukemic cells are halted at distinct stages along 
the differentiation pathway. The potential applicability of 
differentiation-triggering agents is underscored by the suc- 
cess of both the retinoic acid differentiation therapy in the 
treatment of acute promyelocytic leukemia and the clinical 
trials of hexamethylene bisacetamide on myelodysplastic 
~yndrome.'~~'~" Our studies on the U937-C361 cells have 
shown the inducibility of the CD1 I C  gene promoter activity 
during myeloid differentiation. The availability of a differen- 
tiation-responsive promoter will  be also helpful for the con- 
struction of additional stable transfectants in other myeloid 
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Fig 7. A hypothetical model for the induction of the CDllc gene during U937 myeloid differentiation is shown. Phorbol-esters or GM-CSF, 
through PKC activation,  increase  AP-1 activity and promote the expression  of numerous genes and a transient early enhancement in  the CDllc 
gene transcription. At later time points,  AP-1 activity together with  newly expressed  factors  could drive the myeloid-specific differentiation- 
regulated expression  of CDllc. On the other hand, SB would act preferentially through the  -99/-61 region of the promoter, in a myeloid- 
specific manner. The simultaneous action  of both signaling  cascades would be responsible  for the observed  synergy between SB and PMA 
(or GM-CSFI. Dotted lines represent the contributions that  -99/-61 and AP-l sequences play in the PMA- or SB-responsiveness,  respectively. 
At the major transcriptional start site,  GM-CSF  and PMA, through their opposite effects  on c-myc  level^/^.^ would impair (PMA, white arrows) 
or facilitate (GM-CSF, black arrows) transcription factor 11-1 activity at  the Inr, therefore lowering (GM-CSF) or increasing (PMA)  the basal 
transcription initiation from the CDllc lnr.’2.32 Although not depicted, SB treatment also  leads to an  almost complete downregulation of c- 
myc at early time points.” 
cell lines (HL-60, KGI, and THP-I) representative of differ- 
ent stages of the myeloid differentiation pathway,’ thus 
allowing the identification of differentiation-inducing agents 
with potential therapeutic value and the dissection of the 
underlying molecular mechanisms. In this regard, our pre- 
liminary results on VP-16 support the proposed implication 
of PKC  and AP-I in the VP-16-induced U937 myeloid  cell 
differentiation?5 Furthermore, the identification of an SB- 
responsive regulatory region  within the CD1 I C  promoter will 
contribute to the knowledge of the precise mechanism of 
action of butyrate, a natural fatty-acid with a number of 
reported clinical  application^?"^' 
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